title: Circulating DNA in Egyptian Women with Breast Cancer.
abstract: The commonest cancer in Egyptian females occurs in the breast cfDNA is a non-invasive marker for tumor detetion and prognostic assessment in many types of cancer including breast cancer. This study aimed to assess the role of cfDNA and its fragmentation pattern in breast cancer prognosis and treatment response. Forty female patients with malignant breast tumors and a comparable group of healthy blood donors were enrolled prospectively. cfDNA levels and fragmentation patterns were investigated after cfDNA extraction, gel electrophoresis and gel analysis. The percentage of breast cancer patients positive for cfDNA (92.5%) was significantly higher than that of controls (55%). Also, mean concentration of cfDNA was significantly higher than in the control group (<0.05). Most Her-2 positive patients had long cfDNA fragments, this being significant as compared to Her-2 negative patients (<0.05). Metastasis was also positively linked to significantly higher cfDNA (<0.05) and the mean cfDNA integrity index was significantly higher in non-responders compared to treatment responders (<0.05). In conclusion, both qualitative and quantitative aspects of cfDNA and its different fragments in breast cancer patients could be related to prognosis, metastasis and treatment response. Long cfDNA fragments could be particularly useful for prediction purposes.
authors.affiliation: Biochemistry Department, Faculty of Pharmacy for Girls -Al Azhar University, Cairo, Egypt E-mail : emanhssn@yahoo.com.
authors.forename: Iman Hassan
authors.initials: IH
authors.lastname: Ibrahim
authors.forename: Mahmoud M
authors.initials: MM
authors.lastname: Kamel
authors.forename: Mohamed
authors.initials: M
authors.lastname: Ghareeb
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood / Q000235:genetics*; D001943:Breast Neoplasms / Q000235:genetics / Q000473:pathology* / Q000628:therapy; D018270:Carcinoma, Ductal, Breast / Q000235:genetics / Q000556:secondary* / Q000628:therapy; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000235:genetics / Q000556:secondary* / Q000628:therapy; D016022:Case-Control Studies; D003131:Combined Modality Therapy; D004273:DNA, Neoplasm / Q000097:blood / Q000235:genetics*; D004534:Egypt; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D011446:Prospective Studies
chemical_list: D014408:Biomarkers, Tumor; D004273:DNA, Neoplasm